US Specialty Formulations LLC

Startup

USSF located in Allentown, Pennsylvania, Dr. Flanigan is leading his team to bring QYNDR, an oral mucosal vaccine delivery platform currently targeting the COVID-19 vaccine, to market – one that will be easier to use, longer lasting and with fewer side effects. USSF is a thriving biotech and pharmaceutical facility. Today, the 41,000-square-foot manufacturing facility spans over two acres and has become a hub of experts creating diverse solutions, applications and approaches to help clients overcome hurdles in drug discovery and development. USSF provides clinical materials for several clinical trials being conducted both in the USA and abroad.  
 
With a credentialed portfolio that includes a range of vaccine candidates, small molecule formulations, and botanical pharmaceutical-grade extracts, USSF, along with Co-founder and COO Dr. Garry Morefield, Dr. Flanigan has the expertise and equipment to bring a safe, accessible mucosal COVID-19 vaccine to market. They pivoted the formula from an oral DTaP (Diphtheria), a childhood vaccine most of the population received initially targeted for human clinical trials in early 2020. 
 
USSF is a minority-controlled business. The company produces under-contract sterile injectables, topicals and other specialty pharmaceuticals. It manufactures its own branded prescription products, in addition to providing clinical materials for investigational new drug applications, specialty formulations, adjuvants and fermentation and purification services requested by a variety of biotech companies. For more information visit: https://ussfgmp.com/